This commentary on a study comparing use of the brand-name drug Depakene with generic valproic acid to control seizures in people with mental retardation notes the importance of distinguishing between Depakene and Depakote, which is an enteric-coated formulation for which there is no generic form currently available. (DB)

This study evaluated effects on 77 institutionalized patients with mental retardation of changing from anticonvulsant Depakote to the similar drug, Depakene. Results showed no changes in seizure control, less lethargy on Depakene, but some increase in diarrhea and some changes in psychiatric symptoms. Substantial cost savings were achieved by the…

Comparison of brand-name Depakene with generic valproic acid medication to control seizures in 64 subjects with mental retardation living in an intermediate care facility found no statistically significant differences in seizures or blood levels. Results suggest use of the generic medication can result in substantial cost savings. (Author/DB)

This commentary on a study comparing use of the brand name drug Depakene with generic valproic acid to control seizures in people with mental retardation focuses on issues of cost-effectiveness. It notes existing guidelines for pharmacoeconomic evaluation and suggests a possible model to include a threshold price (per quality-adjusted life year)…